Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas Pharma concludes dyspepsia agent agreement with Zeria

Astellas Pharma concludes dyspepsia agent agreement with Zeria

11th March 2008

Astellas Pharma has announced that it has concluded an agreement for the co-development and marketing of functional dyspepsia agent Z-338/YM443 (acotiamide hydrochloride) with Zeria.

The compound was discovered by Zeria and is currently being developed by the company in Japan.

Under the terms of the agreement, Zeria will obtain marketing approval for the drug, which will then be marketed by both firms under a single brand name.

The compound is being developed in Europe, Japan and North America as the first therapeutic drug worldwide for the treatment of functional dyspepsia.

Currently, there is no product that has shown efficacy in patients with functional dyspepsia that has received marketing approval.

“Acetylcholine is an important neurotransmitter for gastrointestinal motility and it has been considered that Z-338/YM443 inhibits peripheral acetylcholinesterase activities, resulting in an improvement of delayed gastric emptying,” Astellas reports.

It adds that the compound could therefore be effective as a treatment for the symptoms of functional dyspepsia.

Astellas reports that recent studies show functional dyspepsia is a disease with a high incidence rate.

Last month, Astellas Pharma received a positive opinion from the Committee of Medicinal Products for Human Use of the European Medicines Agency regarding the marketing authorisaiotn of Mycamine (micafungin sodium).

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.